keyword
MENU ▼
Read by QxMD icon Read
search

"rheumatoid arthritis", "mortality"

keyword
https://www.readbyqxmd.com/read/28101910/a-practical-approach-to-vaccination-of-patients-with-autoimmune-inflammatory-rheumatic-diseases-in-australia
#1
REVIEW
Peter Kk Wong, Hanish Bagga, Claire Barrett, Paddy Hanrahan, Doug Johnson, Amel Katrib, Karin Leder, Mona Marabani, Peta Pentony, John Riordan, Ray White, Laurel Young
Autoimmune inflammatory rheumatic diseases (AIIRD) such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are often complicated by infection, which results in significant morbidity and mortality. The increased risk of infection is probably due to a combination of immunosuppressive effects of the AIIRD, comorbidities, and the use of immunosuppressive conventional synthetic disease modifying anti-rheumatic drugs (DMARDS) and more recently, targeted synthetic DMARDS and biologic DMARDS which block specific pro-inflammatory enzymes, cytokines or cell types...
January 19, 2017: Internal Medicine Journal
https://www.readbyqxmd.com/read/28097725/increased-cortical-porosity-in-women-with-hip-fracture
#2
D Sundh, A G Nilsson, M Nilsson, L Johansson, D Mellström, M Lorentzon
BACKGROUND: Hip fractures cause increased mortality and disability and consume enormous healthcare resources. Only 46% of hip fracture patients have osteoporosis at the total hip according to dual-energy X-ray absorptiometry (DXA) measurement. Cortical porosity increases with ageing and is believed to be important for bone strength. OBJECTIVE: To investigate whether older women with hip fracture have higher cortical porosity than controls, and if so whether this difference is independent of clinical risk factors and areal bone mineral density (aBMD)...
January 18, 2017: Journal of Internal Medicine
https://www.readbyqxmd.com/read/28093268/bronchiectasis-rheumatoid-overlap-syndrome-bros-is-an-independent-risk-factor-for-mortality-in-patients-with-bronchiectasis-a-multicentre-cohort-study
#3
Anthony De Soyza, Melissa J McDonnell, Pieter C Goeminne, Stefano Aliberti, Sara Lonni, John Davison, Lieven J Dupont, Thomas C Fardon, Robert M Rutherford, Adam T Hill, James D Chalmers
INTRODUCTION: We studied if Bronchiectasis (BR) and Rheumatoid arthritis (RA) when manifesting as an overlap syndrome (BROS) was associated with worse outcomes than other BR aetiologies applying the Bronchiectasis Severity Index (BSI). METHODS: We interrogated the Bronchiectasis Severity Index (BSI) databases of 1716 patients across 6 centres: Edinburgh, UK (608 patients), Dundee, UK (N=286), Leuven, Belgium (N=253), Monza, Italy (N=201), Galway Ireland (N=242) and Newcastle, UK (N=126)...
January 13, 2017: Chest
https://www.readbyqxmd.com/read/28089982/fragility-fractures-are-associated-with-an-increased-risk-for-cardiovascular-events-in-women-and-men-with-rheumatoid-arthritis-a-population-based-study
#4
Orla Ni Mhuircheartaigh, Cynthia S Crowson, Sherine E Gabriel, Veronique L Roger, L Joseph Melton, Shreyasee Amin
OBJECTIVE: Women and men with rheumatoid arthritis (RA) have an increased risk for fragility fractures and cardiovascular disease (CVD), each of which has been reported to contribute to excess morbidity and mortality in these patients. Fragility fractures share similar risk factors for CVD but may occur at relatively younger ages in patients with RA. We aimed to determine whether a fragility fracture predicts the development of CVD in women and men with RA. METHODS: We studied a population-based cohort with incident RA from 1955 to 2007 and compared it with age- and sex-matched non-RA subjects...
January 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28086844/are-risk-predicting-models-useful-for-estimating-survival-of-patients-with-rheumatoid-arthritis-associated-interstitial-lung-disease
#5
Hanna M Nurmi, Minna K Purokivi, Miia S Kärkkäinen, Hannu-Pekka Kettunen, Tuomas A Selander, Riitta L Kaarteenaho
BACKGROUND: Risk predicting models have been applied in idiopathic pulmonary fibrosis (IPF), but still not validated in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). The purpose of this study was to test the suitability of three prediction models as well as individual lung function and demographic factors for evaluating the prognosis of RA-ILD patients. METHODS: Clinical and radiological data of 59 RA-ILD patients was re-assessed...
January 13, 2017: BMC Pulmonary Medicine
https://www.readbyqxmd.com/read/28079508/management-of-dyslipidemia-in-high-risk-patients-with-recent-onset-rheumatoid-arthritis-targets-still-not-met-despite-specific-recommendations-results-from-the-espoir-cohort-during-the-first-five-years-of-follow-up
#6
Anne Tournadre, Bruno Pereira, Jean-Jacques Dubost, Nathalie Rincheval, Anne Christine Rat, Bernard Combe, Martin Soubrier
OBJECTIVES: Reduction of LDL-cholesterol (LDLc) is essential to decrease the cardiovascular mortality in rheumatoid arthritis (RA). Between 2005 and 2010, French recommendations for dyslipidaemia defined the LDLc target based on the number of cardiovascular risk factors. In 2006, it was recommended to consider LDLc objectives with RA being counted as an additional cardiovascular risk factor. Our objective was to assess lipid target achievement between 2006 and 2010 in a cohort of patients with recent-onset RA...
January 4, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28073800/relationship-between-exposure-to-tumour-necrosis-factor-inhibitor-therapy-and-incidence-and-severity-of-myocardial-infarction-in-patients-with-rheumatoid-arthritis
#7
Audrey S L Low, Deborah P M Symmons, Mark Lunt, Louise K Mercer, Chris P Gale, Kath D Watson, William G Dixon, Kimme L Hyrich
OBJECTIVES: Patients with rheumatoid arthritis (RA) are at increased risk of myocardial infarction (MI) compared with subjects without RA, with the increased risk driven potentially by inflammation. Tumour necrosis factor inhibitors (TNFi) may modulate the risk and severity of MI. We compared the risk and severity of MI in patients treated with TNFi with that in those receiving synthetic disease-modifying antirheumatic drugs (sDMARDs). METHODS: This analysis included patients with RA recruited from 2001 to 2009 to the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis starting TNFi (etanercept/infliximab/adalimumab) and a biologic-naïve comparator cohort receiving sDMARD...
January 10, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28032180/mortality-in-patients-with-rheumatoid-arthritis-a-15-year-prospective-cohort-study
#8
J van den Hoek, H C Boshuizen, L D Roorda, G J Tijhuis, M T Nurmohamed, G A M van den Bos, J Dekker
The aim of this study was to investigate (a) the mortality in a clinical cohort of patients with established rheumatoid arthritis in comparison with the general Dutch population over 15 years, (b) the trend in the mortality ratio during the study period, and (c) causes of death and compare these with the general population. In 1997, a sample of 1222 patients was randomly selected from the register of a large rheumatology outpatient clinic. Their mortality and primary causes of death between 1997 and 2012 were obtained from Statistics Netherlands...
December 28, 2016: Rheumatology International
https://www.readbyqxmd.com/read/28031844/refractory-rheumatoid-vasculitis
#9
Ashok Kumar, Anshul Goel, Mehul Lapsiwala, Suman Singhal
Systemic rheumatoid vasculitis (SRV) can develop in rheumatoid arthritis of long duration and high disease activity. It most commonly manifests as cutaneous vasculitis and mononeuritis multiplex. This can involve any organ of the body and carries very high mortality. We report a case of a young male who had rheumatoid arthritis for the past 15 years and became refractory to standard drugs and anti-TNF agents. He subsequently developed SRV, which started as mononeuritis multiplex. Disease progressed to result in gangrene of hands and feet despite receiving intravenous cyclophosphamide...
November 2016: Oxford Medical Case Reports
https://www.readbyqxmd.com/read/28031164/improvement-in-5-year-mortality-in-incident-rheumatoid-arthritis-compared-with-the-general-population-closing-the-mortality-gap
#10
Diane Lacaille, J Antonio Avina-Zubieta, Eric C Sayre, Michal Abrahamowicz
OBJECTIVE: Excess mortality in rheumatoid arthritis (RA) is expected to have improved over time, due to improved treatment. Our objective was to evaluate secular 5-year mortality trends in RA relative to general population controls in incident RA cohorts diagnosed in 1996-2000 vs 2001-2006. METHODS: We conducted a population-based cohort study, using administrative health data, of all incident RA cases in British Columbia who first met RA criteria between January 1996 and December 2006, with general population controls matched 1:1 on gender, birth and index years...
December 28, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28028867/the-clinical-status-and-economic-savings-associated-with-remission-among-patients-with-rheumatoid-arthritis-leveraging-linked-registry-and-claims-data-for-synergistic-insights
#11
Jeffrey R Curtis, Lang Chen, Jeffrey D Greenberg, Leslie Harrold, Meredith L Kilgore, Joel M Kremer, Daniel H Solomon, Huifeng Yun
INTRODUCTION: Treat to target guidelines recommend achieving remission or low disease activity in rheumatoid arthritis (RA). However, the reduction in adverse events and costs associated with lower disease activity is unclear. METHODS: We used Corrona linked to Medicare data to identify RA patients. Time varying disease activity was measured using Clinical Disease Activity Index (CDAI); outcomes included all-cause hospitalization, a composite of hospitalization or emergency department (ED) visits, mortality, and medical costs...
December 28, 2016: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/28013201/risk-of-serious-adverse-effects-of-biological-and-targeted-drugs-in-patients-with-rheumatoid-arthritis-a-systematic-review-meta-analysis
#12
Simon Tarp, Daniel Eric Furst, Maarten Boers, George Luta, Henning Bliddal, Ulrik Tarp, Karsten Heller Asmussen, Birgitte Brock, Anna Dossing, Tanja Schjødt Jørgensen, Steffen Thirstrup, Robin Christensen
OBJECTIVES: To determine possible differences in serious adverse effects among the 10 currently approved biological and targeted synthetic DMARDs (b/ts-DMARDs) for RA. METHODS: Systematic review in bibliographic databases, trial registries and websites of regulatory agencies identified randomized trials of approved b/ts-DMARDs for RA. Network meta-analyses using mixed-effects Poisson regression models were conducted to calculate rate ratios for serious adverse events (SAEs) and deaths between each of the 10 drugs and control (i...
December 24, 2016: Rheumatology
https://www.readbyqxmd.com/read/27996221/the-practice-of-physical-activity-and-cryotherapy-in-rheumatoid-arthritis-systematic-review
#13
Daniele Peres, Yoshimasa Sagawa, Benoit Dugué, Susana C Domenech, Nicolas Tordi, Clement Prati
INTRODUCTION: Rheumatoid arthritis (RA) is an autoimmune, chronic and inflammatory disease, which the affected patients present a higher cardiovascular mortality rate. Physical Activities (PA) have been identified as the most important strategy to prevent cardiovascular diseases. However, the articular damage and the chronic pain caused by RA challenges its regular practice. Moreover, persons with RA tend to avoid PA due to the fear of exacerbating the inflammatory potential and pain...
December 19, 2016: European Journal of Physical and Rehabilitation Medicine
https://www.readbyqxmd.com/read/27993172/immune-reconstitution-20%C3%A2-years-after-treatment-with-alemtuzumab-in-a-rheumatoid-arthritis-cohort-implications-for-lymphocyte-depleting-therapies
#14
Faye A H Cooles, Amy E Anderson, Tracey Drayton, Rachel A Harry, Julie Diboll, Lee Munro, Nishanthi Thalayasingham, Andrew J K Östör, John D Isaacs
BACKGROUND: Alemtuzumab, an anti-CD52 monoclonal antibody, was administered to patients with RA between 1991 and 1994. We have followed a cohort of recipients since that time and previously reported significant delays in immune reconstitution. Here we report >20 years of follow-up data from this unique cohort. METHOD: Surviving alemtuzumab recipients were age, sex and disease duration matched with RA controls. Updated mortality and morbidity data were collected for alemtuzumab recipients...
December 20, 2016: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/27974101/response-to-methotrexate-predicts-long-term-mortality-of-patients-with-rheumatoid-arthritis-independent-of-the-degree-of-response-results-of-a-re-evaluation-30-years-after-baseline
#15
Carolin Krause, Gertraud Herborn, Juergen Braun, Henrik Rudolf, Siegfried Wassenberg, Rolf Rau, Dietmar Krause
OBJECTIVES: To assess if there is a correlation between the degree of response to treatment with methotrexate (MTX) and long-term mortality in a cohort of patients with rheumatoid arthritis (RA) established in Germany in the early eighties. METHODS: RA patients who had started MTX treatment between 1980 and 1987 were included. One year after baseline, the treatment response was evaluated. Responders were defined as patients with at least 20% decline in the swollen joint count (out of 32 joints) and the ESR with a prednisone dosage <5 mg/day...
December 13, 2016: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/27964792/cardiovascular-disease-in-inflammatory-rheumatic-diseases
#16
REVIEW
Santos Castañeda, Michael T Nurmohamed, Miguel A González-Gay
Chronic inflammatory rheumatic diseases (IRD), including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis, are prevalent conditions worldwide, with a considerable burden on healthcare systems. They are associated with increased cardiovascular (CV) morbidity and mortality. In this review, we focused on the epidemiology, traditional CV risk factors, genetics, and the link between chronic inflammation, atherosclerosis, and CV disease. Remarkably, patients with IRD have higher vulnerability to atheromatous plaques...
October 2016: Best Practice & Research. Clinical Rheumatology
https://www.readbyqxmd.com/read/27940586/patterns-of-interstitial-lung-disease-and-mortality-in-rheumatoid-arthritis
#17
Jorge A Zamora-Legoff, Megan L Krause, Cynthia S Crowson, Jay H Ryu, Eric L Matteson
OBJECTIVE: To characterize a cohort of patients with RA who have interstitial lung disease (ILD) and to assess the utility of previously developed mortality staging systems [gender, age, lung physiology (GAP) and ILD-GAP]. METHODS: All patients with RA and ILD seen at the Mayo Clinic from 1998 to 2014 were identified and manually screened for study inclusion. RA disease characteristics and pulmonary findings including high-resolution CT and pulmonary function testing were evaluated...
December 10, 2016: Rheumatology
https://www.readbyqxmd.com/read/27924645/cardiovascular-outcomes-and-tumour-necrosis-factor-antagonists-in-chronic-inflammatory-rheumatic-disease-a-focus-on-rheumatoid-arthritis
#18
Giuliano Tocci, Delia Goletti, Valentina Marino, Andrea Matucci, Giuseppe Maria Milano, Fabrizio Cantini, Raffaele Scarpa
Many chronic rheumatic diseases have an inflammatory etiology, leading to accelerated atherosclerosis and increased occurrence of vascular diseases. In rheumatoid arthritis (RA), a reduction in cardiovascular (CV) events has been reported under treatments reducing systemic inflammation. Areas covered: Given the central role of tumour necrosis factor alpha (TNFα) in chronic inflammatory conditions and in atherosclerosis, it has been suggested that TNFα-antagonists may reduce CV risk and mortality. Although there are no randomized controlled or head-to-head trials investigating the effect of specific anti-TNF-agents on CV outcomes, observational cohort studies, national registry data, and meta-analyses in RA have reported improved CV outcomes with anti-TNF therapy...
December 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27917637/-cardiovascular-risk-in-rheumatic-diseases
#19
Sabína Oreská, Michal Tomčík
Cardiovascular diseases, as a result of atherosclerosis, are the leading cause of mortality in the world. Atherosclerosis used to be considered as a degenerative impairment of the artery wall. Nevertheless, it is presently rather regarded as an autoimmune process with the involvement of both innate and adaptive immunity. Recently, it was demonstrated that the cardiovascular risk is increased in autoimmune diseases.In the pathogenesis of atherosclerosis in chronic inflammatory diseases both traditional and non-traditional risk factors are important...
2016: Casopís Lékar̆ů C̆eských
https://www.readbyqxmd.com/read/27913876/atherosclerosis-assessment-and-rheumatoid-arthritis
#20
C Bes, S Gürel, G Buğdaycı, O Dikbaş, M Soy
BACKGROUND AND AIM: Rheumatoid arthritis is associated with increased morbidity and mortality due to atherosclerotic cardiovascular diseases. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme of phospholipase A2; it plays an important role in inflammation and atherosclerosis. Herein we aimed to investigate whether Lp-PLA2 activity is associated with atherosclerosis in patients with rheumatoid arthritis and compare the Lp-PLA2 activity with carotid intima media thickness (CIMT)...
December 2, 2016: Zeitschrift Für Rheumatologie
keyword
keyword
102664
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"